



## Extended number of patients benefiting from coverage for Echopulse® treatments in Germany

**Malakoff (France) – March 21, 2016 – THERACLION** (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that two additional German reimbursement organizations, HEK – Hanseatische Krankenkasse – and BKK24, now cover treatment with Echopulse for both fibroadenoma and thyroid nodules.

HEK insures around 0.5 million members in Germany. With its historic roots in the Hansestädte (Northern Trade Union Cities), the Hamburg-based insurer has a focus on the Northern part of Germany. It therefore will be of major importance for at least three of the four recently opened Echotherapy centers. However, it also acts on a national level with regional service centers and this is important because patients may be sent from all over Germany for treatment at one of the Echopulse reference sites. Previously, HEK only covered the treatment of fibroadenoma with Echopulse. By signing the integrated care contract for thyroid nodule treatment, the German insurer now also covers Echopulse's second indication.

BKK24 covers around 100.000 Germans. Founded in 2002 as a result of a merger of 4 independent BKKs, the insurer is based in Lower Saxony but is open to members from all over Germany. BKK24 also covers both indications.

In total, 1.5 million Germans are now covered for Echopulse fibroadenoma treatments and 1 million for thyroid nodule treatment.

*“More and more insurers are covering Echopulse treatments” says Anja Kleber, VP Marketing and Market Access Theraclion, “replacing a major surgical intervention by a non-invasive outpatient procedure is the optimal choice for a health care system”.*

*“We are seeing significant expansion of treatment activity in Germany since the installation of new sites at the end of December,” Says David Caumartin, Theraclion's CEO, “this is mainly due to the fact that insurers have started to offer Echopulse treatments to their members. With the continued extension of reimbursement coverage, patient access to this non-invasive treatment alternative will continue to be broadened and the recently installed sites will quickly be able to treat 10 patients per month and more”.*

### **About Theraclion**

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: [www.theraclion.com](http://www.theraclion.com).



Theraclion is listed on Alternext Paris  
PEA-PME eligible  
Mnemonic: ALTHE - ISIN Code: FR0010120402



**Contact:**

**Theraclion**

David Caumartin  
Chief Executive Officer  
Tel.: +33 (0)1 55 48 90 70  
[david.caumartin@theraclion.com](mailto:david.caumartin@theraclion.com)

**NewCap**

Financial Communication and Relations  
Emmanuel Huynh / Valentine Brouchet  
Tel.: +33 (0)1 44 71 94 94  
[theraclion@newcap.eu](mailto:theraclion@newcap.eu)

**Kalima**

Press Relations  
Estelle Reine-Adélaïde / Florence Calba  
Tel.: + 33 (0)1 44 90 82 54  
[era@kalima-rp.fr](mailto:era@kalima-rp.fr)